Neovii Pharmaceuticals AG Establishes Global Scientific Department
Neovii continues to strengthen its leadership team and capabilities with the appointment of Richard Sachse as Global Chief Scientific Officer. With the appointment of Dr. Sachse, Neovii has set up a Global Scientific Department which comprises all regulatory, medical, and development activities globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005142/en/
Richard Sachse, Global Chief Scientific Officer, Neovii (Photo: Business Wire)
Neovii’s CEO Juergen Pohle commented: “By establishing a Global Scientific Department, Neovii makes another step forward to become a leading biopharmaceutical company in the transplantation segment.” He added: “We are very excited that Richard joins Neovii and will establish the new Global Scientific Department. His deep understanding and long-term experience in clinical development and regulatory activities, as well as his know-how and strong leadership skills, make him the right person to push this role forward and to drive the business into our next chapter.” Dr. Sachse will also join Neovii’s Global Leadership Team.
Dr. Sachse previously held the position of Senior Vice President, Chief Scientific Officer, and Chief Medical Officer at Æterna Zentaris. In this role Dr. Sachse succeeded in designing and completing development programs for FDA drug approval. He draws on more than 20 years of experience in the pharmaceutical industry not only at Æterna Zentaris, but also with Boehringer Ingelheim, UCB, Schwarz Biosciences, Peptor, and Bayer.
Richard Sachse pointed out: “I am excited to join Neovii and to build the new Global Scientific Department comprising regulatory, medical, and development activities. Driving Neovii to become a full-fledged pharmaceutical company is a challenging but rewarding task, and I am certain that my previous experience will highly benefit Neovii. I am enthusiastic to begin working with our in-licensing partners to provide better paths to key markets for the most innovative lines of treatments in transplantation and rare diseases.”
Neovii also appointed former Pfizer executive Alfred Doucette as Global CFO at the beginning of the year. Alfred Doucette has held several senior finance positions within Pfizer and was most recently the Commercial Director for Pfizer Consumer Healthcare for the SEE/CIS/Baltics/Greece & Cyprus, Israel and Turkey regions, bringing a huge wealth of experience in financial management.
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.
Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Lexingtion MA, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
For further information
For further information, please visit www.neovii.com.
For Neovii Pharmaceuticals AG
Daniela Suter, 0041 (0)44 455 84 25
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 18:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)
Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33 | Pressemelding
Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55 | Pressemelding
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk
Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl
Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00 | Pressemelding
Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di